Alex Goldberg

Stereotaxis Inc. (NASDAQ:STXS) and BioScrip Inc. (NASDAQ:BIOS) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 08/14/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Stereotaxis Inc. (NASDAQ:STXS) and BioScrip Inc. (NASDAQ:BIOS).

Stereotaxis Inc. (NASDAQ:STXS) a company that designs, manufactures, and markets cardiology instrument control system in the United States and internationally is currently up (+14.67%) on 2,444,020 shares traded. Stereotaxis Inc. (NASDAQ:STXS) is currently up (+338.61%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Stereotaxis Inc. (NASDAQ:STXS)

BioScrip Inc. (NASDAQ:BIOS) a company that provides home infusion and other home care services, and pharmacy benefit management services in the United States is currently down (-4.72%) on 2,626,716 shares traded after BioScrip announced today the upsizing and pricing of the previously announced registered underwritten public offering of its common stock. BioScrip Inc. (NASDAQ:BIOS) is currently down (-25.26%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about BioScrip Inc. (NASDAQ:BIOS)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com